Table of Contents
STOCKHOLM, Sweden — Moberg Pharma is expanding North American retail distribution of its Kerasal Neurocream, a topical analgesic for foot pain, with a bigger presence for the product at the largest U.S. drug chain.
The Sweden-based company said Monday that Kerasal Neurocream’s distribution at Walgreens is growing from about 1,000 to 7,000 stores.
The additional locations carrying Kerasal Neurocream means that the product has full distribution at major retailers Walgreens, Walmart, CVS/pharmacy and Rite Aid, bringing the total store count to more than 21,000, according to Moberg Pharma.
Launched in September, Kerasal Neurocream has seen a solid start on the sales front as well as a strong consumer response to advertising and positive feedback from retailers and their customers.
"I am very pleased with the expanded distribution and the positive reception of Kerasal NeuroCream from consumers. Kerasal NeuroCream strengthens the Kerasal brand, our leadership in the topical OTC foot care space in the U.S. and our value to retail partners," stated Steve Cagle, chief executive officer of Moberg Pharma North America.
The company reported that 30 million Americans experience frequent foot pain, and many also suffer from cold feet and dry skin. Painful, cold, dry feet may be associated with various conditions, including diabetes, fibromyalgia, shingles, arthritis, joint pain, muscle strain, or trauma.
Kerasal NeuroCream is a natural, triple-action formula that relieves stabbing, burning, tingling foot pain, warms cold feet, and soothes and moisturizes dry skin, Moberg Pharma said. Kerasal NeuroCream is easily applied with a no-mess foam applicator, and the product’s active ingredients — capsaicin and camphor — have a well-established use as topical pain relievers.
"Kerasal NeuroCream’s strong performance in its first few months confirms our strategy. Effective marketing operations in the U.S in combination with our innovation engine continue to deliver value through differentiated products that consumers appreciate," commented Peter Wolpert, CEO of Moberg Pharma AB.
